Data Bridge Market Research analyzes that the global breast cancer diagnostics market is expected to reach the value of USD 8,651.50 million by 2030, at a.
in these patients, we want to avoid as much as possible an over treatment that can be considered in itself as a new disease, so that s why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who s used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard i information, the standard clinical and histopathological information that are - the tumour size, the lymph node involvement, the tumour grade, | the tumour histology, the i expression of the oestrogen. the ai is going to provide - a more comprehensive analysis of all this data and it s - going to complement these
we know that for this type of cancer, the prognosis is good, with more than 90% of patients be able to get rid of the disease. in these patients, we want to avoid as much as possible an over treatment that can be considered in itself as a new disease, so that s why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who s used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard i information, the standard clinical and histopathological information that are - the tumour size, the lymph node involvement, the tumour grade, |
to get rid of the disease. in these patients, we want to avoid as much as possible an over treatment that can be considered in itself as a new disease, so that s why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who s used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard information, the standard clinical and histopathological information that are the tumour size, the lymph node involvement, i the tumour grade, the tumour histology, the expression of the oestrogen. - the ai is going to provide
an over treatment that can be considered in itself as a new disease. so that s why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who s used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard information, the standard clinical and histopathological information that are the tumour size, the lymph node involvement, i the tumour grade, the tumour histology, the expression of the oestrogen. - the ai is going to provide a more comprehensive i analysis of all this data, i and it s going to complement these genomic tests, | this genomic analysis.